MeiraGTx Holdings plc

Together with the second purchase of $25.0 million of royalty notes and $10.0 million proceeds from the sale of the Company s ordinary shares under the agreements with Oberland Capital in July 2026, and the additional $95.0 million upfront payment due from Hologen and associated reimbursements, the Company believes that it will have sufficient capital to fund operating expenses and capital expenditure requirements into the second half of 2028.

SEC original ↗MeiraGTx Holdings plc — Earnings release (8-K exhibit)EX-99Aug 13, 2026

We may not have sufficient cash flows or cash on hand to satisfy our debt obligations or covenants under our financing arrangements, or we may not be able to effectively manage our business in compliance with such covenants.

SEC original ↗MeiraGTx Holdings plc — 10-Q Quarterly report10-QAug 13, 2026

The Company s capital resources and operations to date have been funded primarily with the proceeds from the Company s collaboration and business development activities and private and public equity offerings, as well as proceeds from debt financings.

SEC original ↗MeiraGTx Holdings plc — 10-Q Quarterly report10-QAug 13, 2026

In the future, the Company may seek to raise additional capital through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources to enable it to complete the development and potential commercialization of its product candidates.

SEC original ↗MeiraGTx Holdings plc — 10-Q Quarterly report10-QAug 13, 2026

Food and Drug Administration (FDA), and in the EU has received Priority Medicines, or PRIME, advanced therapy medicinal product, or ATMP, and Orphan Drug Designations from the local regulatory authorities.

SEC original ↗MeiraGTx Holdings plc — Earnings release (8-K exhibit)EX-99Aug 13, 2026

Up to $400 Million Strategic Investment from Oberland Capital: In June 2026, MeiraGTx entered into an agreement with Oberland Capital Management LLC (Oberland Capital) for an investment of up to $400 million, including up to $375 million in non-dilutive capital in exchange for low single-digit capped royalties on certain products and up to $25 million in equity investment.

SEC original ↗MeiraGTx Holdings plc — Earnings release (8-K exhibit)EX-99Aug 13, 2026

AAV-AIPL1 for LCA4: MeiraGTx entered into a strategic collaboration with Eli Lilly and Company (Lilly), granting Lilly worldwide exclusive rights to meduretgene parvec, or medu-vec (formerly referred to as AAV-AIPL1) for the treatment of Leber congenial amaurosis 4 (LCA4).

SEC original ↗MeiraGTx Holdings plc — Earnings release (8-K exhibit)EX-99Aug 13, 2026

The increase of $2.4 million was primarily driven by taxable income generated from strategic collaboration and other non-recurring transactions, partially offset by valuation allowances and losses in jurisdictions where no tax benefit was recognized.

SEC original ↗MeiraGTx Holdings plc — Earnings release (8-K exhibit)EX-99Aug 13, 2026

Our review of potential strategic transactions may not result in an executed or consummated transaction or other strategic alternative and may not result in anticipated benefits to us or our shareholders, and the process of reviewing strategic transactions or its conclusion could be disruptive and distracting to our business operations and management.

SEC original ↗MeiraGTx Holdings plc — 10-Q Quarterly report10-QAug 13, 2026

These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under Item 1A.

SEC original ↗MeiraGTx Holdings plc — 10-Q Quarterly report10-QAug 13, 2026

These risks and uncertainties include, among others, the following: We have incurred significant losses since inception and anticipate that we will incur continued losses for the foreseeable future, and may never achieve or maintain profitability.

SEC original ↗MeiraGTx Holdings plc — 10-Q Quarterly report10-QAug 13, 2026

Legal Proceedings 54 Item 1A.

SEC original ↗MeiraGTx Holdings plc — 10-Q Quarterly report10-QAug 13, 2026

The success of the Company is subject to certain risks and uncertainties, including, among others: uncertainty of product development; competition in the Company s field of use; uncertainty of capital availability; uncertainty in the Company s ability to enter into agreements and consummate transactions with collaborative partners; expanding and protecting the Company s intellectual property portfolio; dependence on third parties; and dependence on key personnel.

SEC original ↗MeiraGTx Holdings plc — 10-Q Quarterly report10-QAug 13, 2026

Risks and Uncertainties The Company operates in an industry that is subject to intense competition, government regulation and rapid technological change.

SEC original ↗MeiraGTx Holdings plc — 10-Q Quarterly report10-QAug 13, 2026

The Company s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks, including the potential risk of business failure.

SEC original ↗MeiraGTx Holdings plc — 10-Q Quarterly report10-QAug 13, 2026